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Introduction: Several pharmacologic treatments are available for fibromyalgia, but little is known about the
comparative effectiveness of these treatments on health care utilization.
Methods: Using US commercial insurance claims data (covering 2007 to 2009), we conducted a cohort study to
examine the comparative effectiveness of amitriptyline, duloxetine, gabapentin, and pregabalin on health care
utilization in patients with fibromyalgia. We measured patients’ medication adherence using the proportion of days
covered (PDC) and estimated multivariable rate ratios (RRs) for outpatient visits, prescriptions, hospitalization, and
emergency department (ED) visits in propensity score (PS)–matched cohorts.
Results: Cohorts of 8,269 amitriptyline, 9,941 duloxetine, and 18,613 gabapentin initiators were compared with their
PS-matched pregabalin initiators. During the baseline 180-day period, patients had, on average, seven to nine
physician visits, including six to eight specialist visits, and received eight prescription drugs. The mean PDC up to
180 days varied from 38.6% to 67.7%. The number of outpatient visits, prescriptions, and hospitalizations decreased
slightly after initiating one of the study drugs, but the number of ED visits increased after treatment initiation.
Compared to pregabalin, duloxetine was associated with decreased outpatient visits (RR, 0.94; 95% confidence
interval (CI), 0.88 to 1.00), prescriptions (RR, 0.94; 95% CI, 0.90 to 0.98), hospitalizations (RR, 0.75; 95% CI, 0.68 to 0.83),
and ED visits (RR, 0.85; 95% CI, 0.79 to 0.91). Little difference in health care utilization rates was noted among
amitriptyline and gabapentin initiators compared to those who were started on pregabalin.
Conclusions: Fibromyalgia patients had high health care utilization before and after initiation of amitriptyline,
duloxetine, gabapentin, or pregabalin. Medication adherence was suboptimal. Overall, fibromyalgia treatment had
little impact on reducing health care utilization, but duloxetine initiators had less health care utilization than those
started on pregabalin.Introduction
Fibromyalgia is a common, highly disabling syndrome
characterized by chronic widespread pain, fatigue, and
problems with sleep, memory, and mood [1-3]. Treat-
ment of fibromyalgia is challenging and often requires
both pharmacologic and nonpharmacologic treatments
[4,5]. For pharmacologic treatment, tricyclic antidepres-
sants (TCAs) such as amitriptyline, selective serotonin
reuptake inhibitors (SSRIs), serotonin and noradrenaline* Correspondence: skim62@partners.org
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stated.reuptake inhibitors (SNRIs) such as duloxetine and mil-
nacipran, and monoamine oxidase inhibitors are used to
reduce pain, depression, fatigue, and health-related qual-
ity of life [6,7]. Gabapentin and pregabalin are also com-
monly prescribed to ameliorate pain and sleep problems
associated with fibromyalgia [6,7].
Patients with fibromyalgia are known to be heavy users
of health care systems, including outpatient visits, hospi-
talizations, and prescription drug use [8-10]. Despite the
number of available drugs for fibromyalgia, few studies
have directly compared the effects of different pharma-
cologic agents for fibromyalgia on health care utilization.
In studies comparing pre- and posttreatment, pregabalin
initiators had increased inpatient and outpatient visitsis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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had decreased inpatient and outpatient visits after initi-
ating duloxetine [11-13]. In another study, researchers
reported increases in total health care costs after ini-
tiating treatment with pregabalin or duloxetine for fibro-
myalgia [10]. In a study comparing pregabalin to TCAs,
pregabalin initiators had increased total health care costs
from pretreatment to follow-up [14]. Although all of
these studies were performed using US claims data, the
effects of fibromyalgia treatment on health care uti-
lization may vary across different health care systems,
particularly across different countries.
The objective of this study was to examine the com-
parative effectiveness of four commonly used drugs for
fibromyalgia—amitriptyline, duloxetine, gabapentin, and
pregabalin—on the rate of health care utilization in a US
population-based cohort of commercially insured pa-
tients with fibromyalgia. Patients’ adherence to these
drug regimens (that is, continuation or discontinuation)
was also assessed. We hypothesized that the effect of
amitriptyline, duloxetine, or gabapentin on health care
utilization would differ from the effect of pregabalin.
Methods
Data source
We conducted a cohort study using claims data obtained
from UnitedHealthcare, a US commercial health insur-
ance plan, which insures primarily working adults and
their family members, for the period from 1 January 2007
to 31 December 2009. The details of the data source are
presented elsewhere [15]. The study protocol was ap-
proved by the Institutional Review Board of the Brigham
and Women’s Hospital. Patients’ informed consent was
not required by the Institutional Review Board, as the
dataset was deidentified to protect subject confidentiality.
Study cohort
Among patients ages 18 years and older who had at least
one visit coded with the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD
9-CM), code 729.1x, for fibromyalgia, new users of a study
drug—amitriptyline, duloxetine, gabapentin, or pregabalin
—were identified. Milnacipran users were initially consid-
ered, but they were subsequently excluded because of the
small number of patients taking milnacipran (less than
0.5% of all subjects). To be included in the study cohort,
we required patients to have at least 180 days of continu-
ous health plan eligibility before receiving the first pre-
scription of a study drug. Patients were required to be
naïve to all four drugs during the 180-day baseline period.
We excluded patients who were prescribed more than one
study drug at the same index date.
Follow-up time started on the index date, defined as
the dispensing date of the first study drug, and ended atthe first of any of the following censoring events: discon-
tinuation or switching of study drugs, loss of health plan
eligibility, end of study database, or death.
Health care utilization
Changes in health care utilization factors (for example,
the number of outpatient visits to any physicians, pri-
mary care physicians and any specialists; number of pre-
scription drugs; acute care hospitalizations; emergency
department (ED) visits; physical therapy) were assessed
during follow-up.
Covariates
Variables potentially related to fibromyalgia symptoms, ini-
tiation of the study drugs, or health care utilization were
assessed using data from the 180-day baseline period.
These variables included age, sex, fibromyalgia-related co-
morbidities (back pain, chronic headache, depression,
anxiety, chronic pain, fatigue, sleep disorder, and abdo-
minal pain condition), other comorbidities (hypertension,
diabetes, stroke, cardiovascular disease, malignancy, and
inflammatory arthritis), use of other medications (opioids,
benzodiazepines, anticonvulsants excluding gabapentin and
pregabalin, TCAs excluding amitriptyline, SSRIs, SNRIs
excluding duloxetine, other antidepressants, muscle relax-
ants, nonbenzodiazepine sleep disorder drugs, oral gluco-
corticoids, nonsteroidal anti-inflammatory drugs (NSAIDs),
topical analgesics, migraine drugs, and gastrointestinal
protective drugs), and health care utilization factors (num-
ber of outpatient visits to any physicians, primary care
physicians, and specialists; number of prescription drugs;
physical therapy; ED visits; and acute hospitalizations)
[15,16]. Additional files 1 and 2 contain the lists of
diagnoses and procedure codes and medications. To
quantify patients’ comorbidities, we also calculated the
Deyo-adapted Charlson Comorbidity Index based on
the ICD-9-CM [17,18].
Statistical analysis
We compared the baseline characteristics among the
initiators of each study drug. To control for potential
confounding by indication, we used propensity score
(PS) estimation [19]. In multivariable logistic regression
models using pregabalin initiators as the common refe-
rence, we estimated a PS. Pregabalin was chosen as the
common reference because (1) we wanted to directly
compare one treatment approved by the US Food and
Drug Administration (FDA) to another FDA-approved
treatment (duloxetine) and other non-FDA-approved
treatments (amitriptyline and gabapentin), and (2) the
number of pregabalin initiators was greater than that of
duloxetine initiators. All the aforementioned baseline co-
variates except health care utilization factors were in-
cluded in the logistic models. Each pair—amitriptyline
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bapentin versus pregabalin—was then matched on the
PS using the greedy matching algorithm [20]. To mea-
sure patients’ adherence to their fibromyalgia treatments,
we calculated the proportion of days covered (PDC) as
the total number of days’ supply provided by prescrip-
tions for a given study drug up to 180 days from the
index date divided by 180 days.
Adjusting for baseline health care utilization factors, we
used multivariable Cox models to estimate rate ratios (RR)
for ED visits, acute care hospitalizations, and physical
therapy during the follow-up period in all three PS-
matched pairs [21]. Multivariable Poisson regression, ad-
justed for baseline health care utilization factors, was used
to estimate RR for outpatient visits to any physician, pri-
mary care physicians, and any specialists, as well as the
number of prescription drugs, during the follow-up period
in all three PS-matched pairs. To deal with the potential
overdispersion in Poisson models, the standard errors
were adjusted with the scale option in SAS 9.3 software
(SAS Institute, Cary, NC, USA). To assess a long-term ef-
fect of treatment, a subgroup analysis using multivariable
Poisson and Cox regression models was performed in
patients with treatment duration of at least 180 days. All
analyses were done using SAS 9.3 software.Results
Study cohort
Among 116,183 patients who had at least one diagnosis
of fibromyalgia between 2007 and 2009, we identified
13,404 amitriptyline, 18,420 duloxetine, 23,268 gabapen-
tin, and 19,286 pregabalin initiators [15]. Of those, 8,269
amitriptyline, 9,941 duloxetine, and 18,613 gabapentin
initiators were matched to pregabalin initiators on their
PS with a ratio of 1:1. Thus, different subsets of pregaba-
lin users were compared for each pairwise analysis.Baseline characteristics
Demographic characteristics, comorbidities, and medi-
cations at baseline were well balanced and statistically
not different between the PS-matched cohorts (Table 1).
The mean age ranged from 47.7 to 50.0 years, depending
on the treatment pairs. The majority of patients were
women (77% to 82%). The median starting daily doses
were 25 mg for amitriptyline, 60 mg for duloxetine,
300 mg for gabapentin, and 75 mg for pregabalin. Back
pain was the most common comorbidity (52% to 63%),
followed by hypertension (30% to 36%). During the 180-
day baseline, more than one-half of patients received at
least one prescription for opioids and one-third used
benzodiazepines. Use of SSRIs, non-SSRIs/SNRIs antide-
pressants, muscle relaxants, oral steroids, and NSAIDs
was also common.On average, patients had 7.4 to 8.8 outpatient visits
and 5.9 to 7.7 specialist visits during the 180-day base-
line period. The mean number of prescription drugs at
baseline was also high, between 7.9 and 8.4. Approxi-
mately 10% to 12% of patients had at least one ED visit
and 10% to 14% had at least one acute hospitalizations
during the 180-day baseline period.
Continuation of fibromyalgia medication
The mean (standard deviation (SD)) duration of treat-
ment was 77 (92) days for the amitriptyline-pregabalin
pairs, 94 (110) days for the duloxetine-pregabalin pairs,
and 82 (97) days for the gabapentin-pregabalin pairs.
The mean (SD) PDCs up to 180 days of follow-up for
the amitriptyline and pregabalin pair were 38.6% (30.1)
and 50.0% (31.2), respectively. Among the amitriptyline
and pregabalin initiators, 7.9% remained on the treat-
ment for at least 180 days. For the duloxetine and prega-
balin pair, the mean (SD) PDC values were 55.0% (34.0)
and 67.8% (33.4), respectively. Among duloxetine and
pregabalin initiators, 16.5% and 8.3%, respectively,
remained on the treatment for at least 180 days. The
mean PDCs (SD) up to 180 days of follow-up were
45.0% (32.5) for gabapentin initiators and 55.4% (32.4)
for pregabalin. Among gabapentin and pregabalin initia-
tors, 9.0% and 9.9%, respectively, remained on the treat-
ment for at least 180 days (Table 2). Of the patients who
remained on the treatment for 180 days, the dose was
increased in only 5.7% of amitriptyline, 8.7% of duloxe-
tine and gabapentin, and 13.9% of pregabalin initiators.
Changes in health care utilization rates
The mean number of outpatient visits and the pro-
portion of patients with at least one hospitalization
numerically decreased slightly after treatment initiation
compared to before treatment initiation. The number of
prescription drugs did not change, and the proportion of
patients with at least one ED visit or at least one phy-
sical therapy visit increased after treatment initiation in
all groups. In the amitriptyline and pregabalin pair, 4.2%
of patients taking amitriptyline and 4.5% of patients
taking pregabalin were started on another study drug du-
ring follow-up. Similarly, 5.6% of duloxetine and 7.1% of
pregabalin initiators were prescribed another study drug
during follow-up. In the gabapentin-pregabalin pair, 11.5%
of gabapentin initiators and 13.8% of pregabalin initiators
received another study drug during follow-up. Table 3
shows patients’ unadjusted health care utilization patterns
before and after treatment initiation.
In multivariable Poisson and Cox regression analyses
(Table 4), duloxetine initiation was associated with sig-
nificantly decreased outpatient visits (RR, 0.94; 95% CI,
0.88 to 1.00), prescription drug use (RR, 0.94; 95% CI,
0.90 to 0.86), hospitalizations (RR, 0.75; 95% CI, 0.68 to
Table 1 Baseline characteristics of the propensity score–matched cohorts in the 180 days prior to initiation of
amitriptyline, duloxetine, gabapentin, or pregabalina
Amitriptyline Pregabalin Duloxetine Pregabalin Gabapentin Pregabalin
Number of patients 8,269 8,269 9,941 9,941 18,613 18,613
Demographics
Age (yr) 47.7 ± 12.4 47.7 ± 11.7 48.3 ± 11.6 48.2 ± 11.4 50.0 ± 12.6 50.0 ± 11.8
Female 79.6 79.8 82.0 82.0 77.3 77.6
Comorbidities
Back pain 52.4 52.5 55.3 55.7 63.2 63.3
Headache 26.0 26.3 22.2 22.6 21.6 21.7
Depression 10.6 10.5 16.3 16.7 12.0 12.1
Anxiety 12.6 12.7 15.9 16.6 13.0 13.0
Abdominal pain 4.4 4.3 4.2 4.0 3.5 3.6
Neuropathic pain 25.4* 33.4* 30.4* 36.1* 41.6* 40.5*
Sleep disorder 16.7 16.2 18.3 18.4 16.5 16.5
Diabetes 11.5 11.3 12.7 12.8 15.9 15.8
Hypertension 29.8 30.0 31.6 31.2 35.7 35.7
Cardiovascular disease 2.0 2.0 2.0 2.1 3.0 2.9
Stroke 3.2 3.1 3.2 3.0 4.0 3.8
Inflammatory arthritis 10.8 10.7 12.9 13.2 13.6 13.9
Malignancy 4.5 4.6 4.8 4.6 5.9 5.8
Comorbidity index scoreb 0.5 ± 1.0 0.5 ± 1.0 0.6 ± 1.0 0.6 ± 1.0 0.7 ± 1.2 0.7 ± 1.2
Medications
Opioids 55.3 56.1 59.8 59.5 68.2 68.5
TCAsc 10.9 10.4 3.9 3.9 4.8 4.7
SSRIs 18.4 17.7 22.1 22.6 21.4 21.6
SNRIsd 5.4 5.7 17.8 17.1 8.6 8.7
Anticonvulsantse 12.5 11.8 17.5 17.3 39.0 39.0
Other antidepressants 11.4 11.7 17.1 17.3 15.4 15.6
BZDs 29.9 29.7 36.5 36.6 35.2 35.2
Sleeping disorder drugsf 19.9 20.2 23.3 22.6 21.3 21.9
Migraine drugs 8.3 8.7 7.4 7.7 6.9 6.9
Muscle relaxants 31.1 31.6 33.2 33.2 39.3 39.6
Topical analgesics 3.5 3.6 4.5 4.7 6.7 6.8
Oral steroids 26.5 26.2 26.3 26.3 31.0 31.3
NSAIDs 33.6 33.4 35.0 34.9 40.4 40.8
GI protective drugs 21.9 21.9 22.6 22.5 25.2 25.4
Health care utilizationg
Outpatient visits, n 7.4 ± 6.9* 7.7 ± 7.3 8.3 ± 7.5 8.2 ± 8.2 8.8 ± 8.4* 8.6 ± 8.1
PCP visits, n 3.6 ± 3.6 3.5 ± 3.5 3.8 ± 3.5 3.7 ± 3.7 3.9 ± 4.2* 3.8 ± 3.7
Specialist visits, n 5.9 ± 7.3* 6.4 ± 8.0 6.5 ± 7.9* 6.8 ± 9.4 7.6 ± 8.8 7.7 ± 9.5
Prescription drugs, n 7.9 ± 5.4 8.0 ± 5.2 8.6 ± 5.4 8.6 ± 5.4 9.4 ± 5.7* 9.2 ± 5.6
Acute hospitalizations, n 9.8* 10.9 9.9* 11.2 14.2* 13.3
ED visits, n 11.8* 10.5 9.9 10.3 12.4* 10.9
aBZDs, Benzodiazepines; ED, Emergency department; GI, Gastrointestinal; NSAIDs, Nonsteroidal anti-inflammatory drugs; PCP, Primary care physician; SNRI, Serotonin
and norepinephrine reuptake inhibitor; SSRI, Selective serotonin reuptake inhibitor; TCA, Tricyclic antidepressant. Data are expressed as percentage or mean ± SD.
bDeyo-adapted Charlson Comorbidity Index [17,18]. cAll TCAs except amitriptyline. dAll SNRIs except duloxetine. eAll anticonvulsants except gabapentin and pregabalin.
fNonbenzodiazepine drugs only. gNot included in the PS model. *Statistically significant difference compared to the reference group (P < 0.05).
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Table 2 Patients’ continuation of fibromyalgia treatmenta
Amitriptyline Pregabalin Duloxetine Pregabalin Gabapentin Pregabalin
Number of patients 8,269 8,269 9,941 9,941 18,613 18,613
Treatment duration
0 to 90 days 80.9 79.7 63.5 78.6 78.1 75.7
91 to 180 days 11.2 12.4 20.0 13.0 13.0 14.3
181 to 270 days 3.4 4.1 7.6 4.2 4.2 4.9
271 to 365 days 2.1 1.7 4.0 1.7 2.1 2.2
Over 365 days 2.4 1.2 4.9 2.5 2.7 2.8
PDC up to 180 days 38.6 ± 30.1 50.0 ± 31.2 55.0 ± 34.0 67.8 ± 33.4 45.0 ± 32.5 55.4 ± 32.4
aPDC, Proportion of days covered. Data are percentage or mean ± SD.
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physical therapy visits (RR, 0.81; 95% CI, 0.71 to 0.92),
compared to pregabalin. Amitriptyline initiators had
similar rates of health care utilization, except for the sig-
nificantly lower rate of hospitalization (RR, 0.70; 95% CI,
0.62 to 0.80) and outpatient visits (RR, 0.91; 95% CI,
0.84 to 0.99), compared to pregabalin. Little difference
in the rate of health care utilization existed between
gabapentin and pregabalin initiators.
In a subgroup of patients who received at least 180 days
of treatment, amitriptyline, duloxetine, and gabapentin
initiators had lower rates of outpatient visits and specialist
visits compared to pregabalin initiators (Table 5).
Discussion
In this large, US population-based cohort study, patients
newly prescribed amitriptyline, duloxetine, gabapentin,
or pregabalin for fibromyalgia generally had high health
care utilization before and after treatment initiation.
None of the four fibromyalgia treatments seemed to
have much impact on health care utilization; however,
duloxetine initiators had significantly fewer outpatient
and ED visits and hospitalizations, less prescription drug
use, and fewer physical therapy appointments compared
to pregabalin initiators. As reported in prior research,
depression is a predictor of high health care use [22].
The beneficial effect of duloxetine versus pregabalin seen
in this study may be attributable to the fact thatTable 3 Crude changes in health care utilization pre- and pos
Amitriptyline Pregabalin
Pre Post Pre Post
Mean number of outpatient visits 7.4 5.5 7.7 6.2
Mean number of PCP visits 3.6 2.8 3.5 2.8
Mean number of specialist visits 5.9 4.3 6.4 5.0
Mean number of prescription drugs 7.9 7.9 8.0 8.3
Any acute hospitalization (%) 9.8 5.6 10.9 7.9
Any ED visit (%) 11.8 12.4 10.5 13.4
Physical therapy (%) 4.4 7.4 5.1 9.7
aED, Emergency department; PCP, Primary care physician.duloxetine is also an antidepressant and thus manages
depressive mood in patients with fibromyalgia. Amitrip-
tyline initiators also had fewer hospitalizations and phy-
sical therapy visits during follow-up than pregabalin
initiators did.
Our study highlights several important issues in the
management of fibromyalgia. First, fibromyalgia drugs ap-
pear to have little effect on reducing health care utilization
by patients with fibromyalgia, as seen in previous studies
of pregabalin, duloxetine, and TCAs [10-13]. Whether the
lack of effect on health care utilization is due to inad-
equate benefits or concurrent benefit with new side effects
of treatment is unclear. It is also difficult to determine
whether the use of health care was inappropriately high or
clinically necessary. Second, discontinuation rates are high
across all study drugs. In previous studies, researchers
have found that the effectiveness of these medications is
limited [23], and many patients discontinue these medica-
tions due to side effects [24]. Third, pharmacologic treat-
ment alone may not be effective in fibromyalgia [25]. Prior
meta-analyses of various nonpharmacologic treatments
such as massage therapy, aquatic physical therapy, balneo-
therapy, and hydrotherapy showed mixed results on fibro-
myalgia symptoms [25-28], although beneficial effects of
aerobic exercise and cognitive behavioral therapy on pain
and mood were consistently noted [29,30]. Nonetheless,
in future longitudinal study, investigators should explore
the utility of multifaceted approaches to the treatment oft–index date among propensity score–matched cohortsa
Duloxetine Pregabalin Gabapentin Pregabalin
Pre Post Pre Post Pre Post Pre Post
8.3 6.3 8.2 6.5 8.8 6.9 8.6 7.0
3.8 2.8 3.7 2.9 3.9 3.1 3.8 3.1
6.5 4.7 6.8 5.2 7.6 5.8 7.7 5.9
8.6 8.4 8.6 8.9 9.4 9.3 9.2 9.5
9.9 7.7 11.2 8.4 14.2 9.7 13.3 10.5
9.9 15.5 10.3 14.5 12.4 17.0 10.9 16.9
5.0 7.0 5.2 9.1 6.2 10.8 5.8 10.2
Table 4 Adjusted effect of amitriptyline, duloxetine, and gabapentin, compared to pregabalin, on health care
utilization during the follow-up perioda
Health care utilization Amitriptyline, RR (95% CI)b Duloxetine, RR (95% CI)b Gabapentin, RR (95% CI)b
Outpatient visitsc 0.91 (0.84 to 0.99)* 0.94 (0.88 to 1.00)* 0.94 (0.88 to 1.00)*
PCP visitsc 0.99 (0.90 to 1.09) 0.92 (0.85 to 0.98)* 0.92 (0.85 to 0.98)*
Any specialist visitsc 0.85 (0.77 to 0.95)* 0.89 (0.82 to 0.97)* 0.89 (0.82 to 0.97)*
Prescription drugsc 0.97 (0.91 to 1.03) 0.94 (0.90 to 0.98)* 0.94 (0.90 to 0.98)*
Acute hospitalizationd 0.70 (0.62 to 0.80)* 0.75 (0.68 to 0.83)* 0.95 (0.89 to 1.01)
ED visitsc 0.94 (0.86 to 1.03) 0.85 (0.79 to 0.91)* 1.05 (1.00 to 1.10)
Physical therapyd 0.92 (0.80 to 1.06) 0.81 (0.71 to 0.92)* 1.12 (1.03 to 1.21)
aCI, Confidence interval; ED, Emergency department; PCP, Primary care physician; RR, Rate ratio. bPregabalin was used as the reference group. cMultivariable
Poisson regression was used. dMultivariable Cox proportional hazards regression was used. *Statistically significant difference (P < 0.05). All rate ratios were
adjusted for neuropathic pain and the number of outpatient visits, PCP visits, any specialist visits, prescription drugs, acute hospitalizations, and ED visits
at baseline.
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mental health services, with the goal of reducing health
care utilization.
There are limitations to our study. First, selection of a
drug was not random in this observational cohort. We
used rigorous pharmacoepidemiologic methods in the
study design and data analysis, such as the new user
design and PS-matched analysis, to minimize confounding
by indication [19,31]. However, confounding by unmeas-
ured variables, such as severity or activity of fibromyalgia,
functional status, other comorbidities, use of nonpharma-
cologic treatments, and socioeconomic status, can still be
an issue. For example, differences existed in comorbidities
prior to PS matching, such that duloxetine initiators had a
higher proportion of diagnosis and treatment for depres-
sion (24%) and anxiety (21%) than the pregabalin group
(12% and 13%, respectively) [15]. If the presence or the
severity of such conditions, which are related to use of
health care systems, were incompletely controlled for, this
could lead to residual confounding in our analysis. Sec-
ond, there was also potential for misclassification, as we
relied on diagnosis codes and drug-dispensing records to
select patients with fibromyalgia and identify their comor-
bidities. Third, in this study, the reasons for use of healthTable 5 Adjusted effect of amitriptyline, duloxetine, and gab
utilization in patients with treatment duration of at least 180
Health care utilization Amitriptyline, RR (95% CI)b
Outpatient visitsc 0.91 (0.84 to 0.99)*
PCP visitsc 0.99 (0.90 to 1.09)
Any specialist visitsc 0.85 (0.77 to 0.95)*
Prescription drugsc 0.97 (0.91 to 1.03)
Acute hospitalizationd 0.63 (0.41 to 0.95)*
ED visitsc 1.07 (0.84 to 1.37)
Physical therapyd 0.76 (0.55 to 1.06)
aCI, Confidence interval; ED, Emergency department; PCP, Primary care physician; R
Poisson regression was used. dMultivariable Cox proportional hazards regression wa
adjusted for neuropathic pain and the number of outpatient visits, PCP visits, any s
at baseline.care resources (for example, outpatient and ED visits,
hospitalization) were not available. Fourth, some of the
visits to physicians or EDs may not have been related to
fibromyalgia. Furthermore, the number of physician visits
may not be an appropriate indicator of the effectiveness of
fibromyalgia treatment. Fifth, we did not directly compare
health care utilization between amitriptyline, duloxetine,
and gabapentin initiators. Sixth, although it is possible that
pharmacologic treatment has a beneficial effect on health
care utilization in patients with fibromyalgia compared to
no treatment, our study was designed to examine the
comparative effectiveness of the four study drugs. Seventh,
because access to health care is different in each health in-
surance plan in the United States, our results may not be
generalizable to populations covered by different health
insurance plans, particularly in different countries. Eighth,
we did not examine the effect of combination therapy, but
less than 10% of patients were put on combination ther-
apy during the study period [15].
Conclusions
Fibromyalgia patients had substantial health care utili-
zation before and after initiation of amitriptyline, dulo-
xetine, gabapentin, or pregabalin and generally had highapentin, compared to pregabalin, on health care
daysa
Duloxetine, RR (95% CI)b Gabapentin, RR (95% CI)b
0.94 (0.88 to 1.00)* 0.94 (0.88 to 1.00)*
0.92 (0.85 to 0.98)* 0.92 (0.85 to 0.98)*
0.89 (0.82 to 0.97)* 0.89 (0.82 to 0.97)*
0.94 (0.90 to 0.98)* 0.94 (0.90 to 0.98)*
0.76 (0.57 to 1.01) 0.73 (0.59 to 0.90)*
1.00 (0.83 to 1.19) 1.03 (0.90 to 1.17)
0.85 (0.67 to 1.09) 0.99 (0.82 to 1.19)
R, Rate ratio. bPregabalin was used as the reference group. cMultivariable
s used. *Statistically significant difference (P < 0.05). All rate ratios were
pecialist visits, prescription drugs, acute hospitalizations, and ED visits
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treatment did not substantially decrease health care
utilization. Compared to pregabalin initiators, duloxetine
initiators had less health care utilization during follow-up.
In future studies, researchers should examine the effec-
tiveness of pharmacologic treatments combined with non-
pharmacologic interventions in treating chronic pain, as
well as the use of health care resources in fibromyalgia.
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